TCR-T cells armored with immune checkpoint blockade in EBV-positive nasopharyngeal carcinoma: The first-in-human phase 1/2 trial.

Authors

null

Qingzhu Jia

Institute of Cancer, Xinqiao Hospital, Chongqing, China

Qingzhu Jia , Ling Peng , Gang Chen , Haiyang Wu , Dong Zeng , Tao Liu , Yunpeng Zhan , Si Li , Frank Su , Bo Zhu , Qi-Jing Li

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT04139057

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 6047)

DOI

10.1200/JCO.2023.41.16_suppl.6047

Abstract #

6047

Poster Bd #

39

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Annual Meeting

<span>Phase IIA study of high-affinity TCR-T (TAEST16001) targeting NY-ESO-1 in soft tissue sarcoma.</span>

Phase IIA study of high-affinity TCR-T (TAEST16001) targeting NY-ESO-1 in soft tissue sarcoma.

First Author: Jiayong Liu

First Author: Suzanne Phillips

First Author: Kedar Kirtane